- Home
- TLSI vs NCZ Comparison
TLSI vs NCZ Comparison
Compare TLSI & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- NCZ
- Stock Information
- Founded
- TLSI 2010
- NCZ 2003
- Country
- TLSI United States
- NCZ United States
- Employees
- TLSI N/A
- NCZ N/A
- Industry
- TLSI Medical Specialities
- NCZ Finance Companies
- Sector
- TLSI Health Care
- NCZ Finance
- Exchange
- TLSI Nasdaq
- NCZ Nasdaq
- Market Cap
- TLSI 244.3M
- NCZ 271.0M
- IPO Year
- TLSI N/A
- NCZ N/A
- Fundamental
- Price
- TLSI $4.55
- NCZ $14.25
- Analyst Decision
- TLSI Strong Buy
- NCZ
- Analyst Count
- TLSI 4
- NCZ 0
- Target Price
- TLSI $11.13
- NCZ N/A
- AVG Volume (30 Days)
- TLSI 128.4K
- NCZ 533.0K
- Earning Date
- TLSI 11-13-2025
- NCZ 01-01-0001
- Dividend Yield
- TLSI N/A
- NCZ 12.16%
- EPS Growth
- TLSI N/A
- NCZ N/A
- EPS
- TLSI N/A
- NCZ N/A
- Revenue
- TLSI $35,990,000.00
- NCZ N/A
- Revenue This Year
- TLSI $56.71
- NCZ N/A
- Revenue Next Year
- TLSI $52.25
- NCZ N/A
- P/E Ratio
- TLSI N/A
- NCZ N/A
- Revenue Growth
- TLSI 45.50
- NCZ N/A
- 52 Week Low
- TLSI $3.42
- NCZ $2.50
- 52 Week High
- TLSI $5.88
- NCZ $3.15
- Technical
- Relative Strength Index (RSI)
- TLSI 37.64
- NCZ 56.93
- Support Level
- TLSI $4.50
- NCZ $13.45
- Resistance Level
- TLSI $4.80
- NCZ $14.35
- Average True Range (ATR)
- TLSI 0.22
- NCZ 0.21
- MACD
- TLSI -0.05
- NCZ 0.02
- Stochastic Oscillator
- TLSI 0.00
- NCZ 82.70
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.